LXEO — Lexeo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $528.44m
- $335.06m
- 53
- 23
- 84
- 53
Annual cashflow statement for Lexeo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -5.15 | -50.6 | -59.3 | -66.4 |
| Depreciation | ||||
| Non-Cash Items | 1.87 | 0.387 | 2.66 | 4.84 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.15 | 6.04 | 1.79 | 1.48 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Taxes Payable | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -3.13 | -44.2 | -54.6 | -59.5 |
| Capital Expenditures | 0 | -0.188 | -0.901 | -0.165 |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Cash from Investing Activities | 0 | -0.188 | -0.901 | -0.165 |
| Financing Cash Flow Items | -0.224 | -0.372 | 0 | 100 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 32.4 | 151 | 0.189 | 104 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 29.2 | 106 | -55.3 | 44.1 |